D-serine in Schizophrenia (DSRSZ)
The Effects of Add-On D-serine Pharmacotherapy in Chronic Treatment Resistant Schizophrenia Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Andrea Durrant, PhD
- Phone Number: 972527181489
- Email: andy007israel@gmail.com
Study Contact Backup
- Name: Uriel Heresco-Levy, MD
- Phone Number: 97225316906
- Email: urielh@ekmd.huji.ac.il
Study Locations
-
-
-
Jerusalem, Israel, 91035
- Recruiting
- Herzog Hospital
-
Contact:
- Andrea Durrant, PhD
- Phone Number: 972527181489
- Email: andy007israel@gmail.com
-
Contact:
- Uriel Heresco-Levy, MD
- Phone Number: 97225316906
- Email: urielh@ekmd.huji.ac.il
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- DSM-5 Schizophrenia criteria, able and willing to give informed consent, and comply to study procedure, adequate contraception, post-menopausal or abstinent, PANSS Total Score equal or greater than 70, score of 4 or greater on two psychotic items
Exclusion Criteria:
- clinically significant, uncontrollable or unstable medical condition, mental retardation or severe organic brain syndrome, significant risk of suicide or violent behavior
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo
starch
|
dosage
Other Names:
|
|
High Dose
3.5 g/d D-serine adjuvant treatment
|
dosage
Other Names:
|
|
Low Dose
2.1 g/d D-serine adjuvant treatment
|
dosage
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PANSS Total Score
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HerzogHospital
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
NCT07369401Not yet recruiting
-
NCT01190267CompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
NCT01190254CompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
NCT07184619Recruiting
-
NCT06456983RecruitingSchizophrenia | Treatment Resistant Schizophrenia
-
NCT05944510CompletedTreatment Resistant Schizophrenia
-
NCT07141966Completed
Clinical Trials on D-serine
-
NCT07312110RecruitingParkinson Disease (PD) | Parkinson s Disease
-
NCT00138775UnknownSchizophrenia | Schizoaffective Disorder
-
NCT01459029Unknown
-
NCT03711500CompletedSchizophrenia | Schizo Affective Disorder
-
NCT01804920UnknownTardive Dyskinesia | Schizophrenia and Schizoaffective Disorder
-
NCT04140773TerminatedPsychotic Disorder